106 related articles for article (PubMed ID: 21451504)
1. The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691).
Fidock MD; Souberbielle BE; Laxton C; Rawal J; Delpuech-Adams O; Corey TP; Colman P; Kumar V; Cheng JB; Wright K; Srinivasan S; Rana K; Craig C; Horscroft N; Perros M; Westby M; Webster R; van der Ryst E
Clin Pharmacol Ther; 2011 Jun; 89(6):821-9. PubMed ID: 21451504
[TBL] [Abstract][Full Text] [Related]
2. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection.
Horsmans Y; Berg T; Desager JP; Mueller T; Schott E; Fletcher SP; Steffy KR; Bauman LA; Kerr BM; Averett DR
Hepatology; 2005 Sep; 42(3):724-31. PubMed ID: 16116638
[TBL] [Abstract][Full Text] [Related]
3. First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer.
Dudek AZ; Yunis C; Harrison LI; Kumar S; Hawkinson R; Cooley S; Vasilakos JP; Gorski KS; Miller JS
Clin Cancer Res; 2007 Dec; 13(23):7119-25. PubMed ID: 18056192
[TBL] [Abstract][Full Text] [Related]
4. Association of TLR7 single nucleotide polymorphisms with chronic HCV-infection and response to interferon-a-based therapy.
Schott E; Witt H; Neumann K; Bergk A; Halangk J; Weich V; Müller T; Puhl G; Wiedenmann B; Berg T
J Viral Hepat; 2008 Jan; 15(1):71-8. PubMed ID: 18088248
[TBL] [Abstract][Full Text] [Related]
5. Design and optimisation of orally active TLR7 agonists for the treatment of hepatitis C virus infection.
Tran TD; Pryde DC; Jones P; Adam FM; Benson N; Bish G; Calo F; Ciaramella G; Dixon R; Duckworth J; Fox DN; Hay DA; Hitchin J; Horscroft N; Howard M; Gardner I; Jones HM; Laxton C; Parkinson T; Parsons G; Proctor K; Smith MC; Smith N; Thomas A
Bioorg Med Chem Lett; 2011 Apr; 21(8):2389-93. PubMed ID: 21419626
[TBL] [Abstract][Full Text] [Related]
6. Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist.
Vicari AP; Schmalbach T; Lekstrom-Himes J; Morris ML; Al-Adhami MJ; Laframboise C; Leese P; Krieg AM; Efler SM; Davis HL
Antivir Ther; 2007; 12(5):741-51. PubMed ID: 17713157
[TBL] [Abstract][Full Text] [Related]
7. Delivery with polycations extends the immunostimulant Ribomunyl into a potent antiviral Toll-like receptor 7/8 agonist.
Herberhold S; Coch C; Zillinger T; Hommertgen B; Busch N; Schuberth C; Hartmann E; Wimmenauer V; Hagmann CA; Lüdenbach B; Schlee M; Bootz F; Hartmann G; Barchet W
Antivir Ther; 2011; 16(5):751-8. PubMed ID: 21817197
[TBL] [Abstract][Full Text] [Related]
8. Use of modelling and simulation techniques to support decision making on the progression of PF-04878691, a TLR7 agonist being developed for hepatitis C.
Jones HM; Chan PL; van der Graaf PH; Webster R
Br J Clin Pharmacol; 2012 Jan; 73(1):77-92. PubMed ID: 21689140
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up after successful interferon therapy of acute hepatitis C.
Wiegand J; Jäckel E; Cornberg M; Hinrichsen H; Dietrich M; Kroeger J; Fritsch WP; Kubitschke A; Aslan N; Tillmann HL; Manns MP; Wedemeyer H
Hepatology; 2004 Jul; 40(1):98-107. PubMed ID: 15239091
[TBL] [Abstract][Full Text] [Related]
10. A frequent functional toll-like receptor 7 polymorphism is associated with accelerated HIV-1 disease progression.
Oh DY; Baumann K; Hamouda O; Eckert JK; Neumann K; Kücherer C; Bartmeyer B; Poggensee G; Oh N; Pruss A; Jessen H; Schumann RR
AIDS; 2009 Jan; 23(3):297-307. PubMed ID: 19114863
[TBL] [Abstract][Full Text] [Related]
11. Activation of anti-hepatitis C virus responses via Toll-like receptor 7.
Lee J; Wu CC; Lee KJ; Chuang TH; Katakura K; Liu YT; Chan M; Tawatao R; Chung M; Shen C; Cottam HB; Lai MM; Raz E; Carson DA
Proc Natl Acad Sci U S A; 2006 Feb; 103(6):1828-33. PubMed ID: 16446426
[TBL] [Abstract][Full Text] [Related]
12. Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection.
Thomas A; Laxton C; Rodman J; Myangar N; Horscroft N; Parkinson T
Antimicrob Agents Chemother; 2007 Aug; 51(8):2969-78. PubMed ID: 17548497
[TBL] [Abstract][Full Text] [Related]
13. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a highly potent series of TLR7 agonists.
Jones P; Pryde DC; Tran TD; Adam FM; Bish G; Calo F; Ciaramella G; Dixon R; Duckworth J; Fox DN; Hay DA; Hitchin J; Horscroft N; Howard M; Laxton C; Parkinson T; Parsons G; Proctor K; Smith MC; Smith N; Thomas A
Bioorg Med Chem Lett; 2011 Oct; 21(19):5939-43. PubMed ID: 21885277
[TBL] [Abstract][Full Text] [Related]
15. Impaired cytokine response in myeloid dendritic cells in chronic hepatitis C virus infection regardless of enhanced expression of Toll-like receptors and retinoic acid inducible gene-I.
Miyazaki M; Kanto T; Inoue M; Itose I; Miyatake H; Sakakibara M; Yakushijin T; Kakita N; Hiramatsu N; Takehara T; Kasahara A; Hayashi N
J Med Virol; 2008 Jun; 80(6):980-8. PubMed ID: 18428149
[TBL] [Abstract][Full Text] [Related]
16. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
Cacoub P; Lidove O; Maisonobe T; Duhaut P; Thibault V; Ghillani P; Myers RP; Leger JM; Servan J; Piette JC
Arthritis Rheum; 2002 Dec; 46(12):3317-26. PubMed ID: 12483738
[TBL] [Abstract][Full Text] [Related]
17. Antiviral effect of human recombinant interleukin-12 in patients infected with hepatitis C virus.
Lee JH; Teuber G; von Wagner M; Roth WK; Zeuzem S
J Med Virol; 2000 Mar; 60(3):264-8. PubMed ID: 10630957
[TBL] [Abstract][Full Text] [Related]
18. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta.
Asahina Y; Izumi N; Uchihara M; Noguchi O; Tsuchiya K; Hamano K; Kanazawa N; Itakura J; Miyake S; Sakai T
Hepatology; 2001 Aug; 34(2):377-84. PubMed ID: 11481623
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of interleukin-8 in hepatitis C virus infection: relation to combined peg-interferon ribavirin response and genotype 4.
El Sayed ZM; Mansour FA; Ghal MF; Abou-Zahra SB
Immunol Invest; 2011; 40(1):29-38. PubMed ID: 20809700
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover.
Zeuzem S; Schmidt JM; Lee JH; von Wagner M; Teuber G; Roth WK
Hepatology; 1998 Jul; 28(1):245-52. PubMed ID: 9657119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
